Background: Distal embolization (DE) events are commonly reported in percutaneous atherectomy procedures. Embolic protection (EP) devices reduce these events. This study compared inpatient hospital costs and resource utilization in two non-coronary (presumed lower extremity) atherectomy patient populations: (1) a DE event group, and (2) an EP group. Methods: All inpatient discharges for atherectomy of non-coronary vessels (ICD-9-CM procedure code 39.50) were selected from a comprehensive hospital admissions database (Premier Perspective CY2005-20 10). DE patients were identified using ICD-9-CM diagnosis codes (444.XX, 434.0, and 434.1). Patients receiving EP devices were identified using a billing data keyword search. Discharges in the DE and EP groups were propensity matched adjusting for age, gender, race and severity scores. Inpatient mortality, length of stay, operating room (OR) time, and costs were compared between the groups. Results: After propensity matching DE and EP groups, there were nϭ1,497 matched pairs. The inpatient mortality rate was significantly higher in DE compared to EP (2.7% vs. 1.3%, pϽ0.05). Hospital stay averaged 1.4 days longer in the DE patients (pϽ0.05). Room and board, surgery and pharmacy costs were significantly higher for DE (pϽ0.05). OR time was 24 minutes longer for DE patients. Total costs were higher but not significant for the DE group ($24,326 vs. $23,594, pϭ0.38) . As a reference, the total rate of embolic events detected in this inpatient population was 13.5 percent. Conclusions: The use of embolic protection is strongly associated with lower inpatient mortality rates, shorter hospital stays, and shorter OR times. Cumulatively, these findings demonstrate embolic protection devices may significantly reduce consumption of hospital resources.
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Drug eluting balloon for below the knee angioplasty-one year results from a single center DEB-BTK Registry
Grigore Popusoi 1 , Angelo Cioppa 1 , Eugenio Stabile 1 , Luigi Salemme 1 , Vittorio Ambrosini 1 , Tullio Tesorio 1 , Giovanni Sorropago 2 , Linda Cota 1 , Armando Pucciarelli 1 , Giancarlo Biamino 1 , Paolo Rubino 1 1 Montevergine clinic, Mercogliano, Avellino, 2 Montevergine clinic, Mercogliano, Avellino Background: Recent registries and randomized trials support the role of percutaneous revascularization in patients with critical limb ischemia (CLI) and life limiting claudication (LLC) due also to infragenicular atherosclerotic disease. However, the percutaneous transluminal angioplasty (PTA) may result in high restenosis rate and target lesion revascularization.Promising results are coming from ond randomised controlled study an single center registries using drug eluting balloon (DEB) in this arterial district. Methods: Between December 2008 and December 2010, 75 (48 males) consecutive patients underwent percutaneous revascularization of below the knee(BTK) arteries in our institution due to CLI(58[72.5%]) and LLC(17[27.5%] ). Functional status was Rutheford class 3 in 4 (5%) patients, class 4 in 24(30%) patients, class 5 in 37(50%), and class 6 in 10(15%). All patients(98 lesions) were treated predilating with an undersized standard balloon and then with Pacltaxel Eluting Balloon In.Pact Amphirion (Medtronic).No limitation in number of vessels treated, lesion length were considered (mean treated length 89Ϯ25 mm). A total occlusion was the target lesion in 47% of cases. In 22 cases above the knee arteries were previously treated.Polpliteal artery was the target lesion in 17 cases, anterior tibial artery in 28 cases, posterior tibial artery in 23 cases, peroneal artery in 16 cases.
Results: Procedural success, meaning angiographic evidence of restored antegrade flow, was achieved in 70 (94%) patients. Bail-out stenting for flow limiting dissection or abrupt target vessel occlusion was needed in 7 patients(10%). Procedural complication:distal embolization 2(2.5%),access site complication 1(1.5%), intra-hospital mortality 1(1,5%).The rate of angiographic restenosis at twelve months was 24% (nϭ15). Only symptomatic patients were planned for a reintervention(nϭ9). One-year primary patency was 76%(nϭ52); secondary patency was 91% (nϭ61). Conclusions: The outcome of this single center experience suggest that the use of drug eluting balloon for percutaneous transluminal angioplasty of below the knee arterial lesions is feasible, safe, and provides favourable one-year clinical results in patients with CLI.
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